Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
13Activity
0 of .
Results for:
No results containing your search query
P. 1
Biotech Directory Victoria

Biotech Directory Victoria

Ratings:

4.0

(2)
|Views: 3,723|Likes:
Published by smart770
Listing of biotech companies in Victoria. Includes all contact details.
Listing of biotech companies in Victoria. Includes all contact details.

More info:

Published by: smart770 on Jul 18, 2009
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as RTF, PDF, TXT or read online from Scribd
See more
See less

02/05/2013

pdf

text

original

 
Access Genetics Pty. Ltd.
ACN 43 091 834 972
Contact:
Mr Donald Coles, Managing Director 
Phone:
+61 3 5797 6203
Fax:
+61 3 5797 6307
Email:
 Address:
295 Maroondah Link HighwayAlexandra, VIC, 3714Australia
Profile:
In March 2000, the proprietor of Valley Seeds Proprietary Limited, Mr Donald Coles, formed a new spin-off company, Access Genetics Pty. Ltd., to specialise in generating cereal grain varietiesusing new breeding techniques. Strategic alliances have been established with US and Europeanbreeders to introduce elite varieties to the breeding program. Access Genetics has licensed to leading German life sciences and chemical company BASF AG akey technology that was developed by the University of Melbourne - a genetic mechanism (malegamete specific promoter) for expressing key genes in specific parts of the plant. Access Geneticsis using this technology and others in a research project at the University of Melbourne, with aimsincluding the production of special purpose wheat varieties for use in healthfoods such as low-calorie breakfast cereal and biscuits. [See separate entry for Valley Seeds].
Acrux Limited 
ACN 72 082 001 152
Contact:
Dr Igor Gonda, Chief Executive Officer/Managing director 
Phone:
+61 3 8379 0100
Fax:
+61 3 8379 0101
Email:
Internet:
 Address:
103-113 Stanley StreetWest Melbourne, VIC, 3003Australia
Profile:
 Acrux Limited is developing and commercializing a new, superior generation of transdermal, skinand healthcare products based on technology initially discovered at Monash University,Melbourne, Australia. The portfolio is developed through investments by Acrux and partnershipswith pharmaceutical and healthcare companies. The Company has a diversified pipeline that includes a Phase 3 program with estradiol, Phase 2b study on the treatment of low libidoassociated with low androgen levels in women, Phase 2 trial on pain management with fentanyl  plus numerous other products at an earlier stage of development.The technology combines widely used GRAS (generally recognised as safe) status compounds toaid delivery of drugs topically and across the skin into the bloodstream with an applicator designed to spray a rapid-drying, metered dose of drug onto the skin. Acrux Ltd licensed the patented technology from Monash University. Acrux’s technology has a number of features that areexpected to provide an improved form of therapy to patients, including:• convenience of use (compared with injections, and tablets, patches or gels)• no skin irritation• cosmetic acceptability (quick-drying, non-occlusive spray)• dosage flexibility • ease of manufacture• low cost of goods• control of drug levels within the blood that minimisze potentially toxic peaks or ineffectivetroughs; and • reduction in the frequency of drug administration (resulting from the slow release of the drug through the skin).Further research and development (preclinical screening) will be conducted in the company’sdedicated laboratories. Manufacturing, clinical and regulatory services will be contracted to local and international contract research organisations. Acrux personnel will manage the delivery of these services. Acrux is organised as a Pooled Development Fund.
Adipogen Pty Ltd 
ACN 102 901 397
 
Contact:
Dr Mark Harvey, Group Manager 
Phone:
+61 7 3365 4037
Email:
Internet:
 Address:
Melbourne UniversityCarlton, VIC, 3053Australia
Postal  Address:
Edith Cavell BuildingRoyal Brisbane HospitalHerston, Queensland, 4029Australia
Profile:
 Adipogen was formed in 2002 by UniQuest, The University of Queensland’s technology commercialisation company. UniQuest has licensed the intellectual property associated with thedevelopment of the new drug to Adipogen, which has attracted seed funding from Uniseed Pty Ltd,the $20 million pre-seed fund formed in 2001 by the UQ and Melbourne University.
 
Advanced Laboratory Solutions Pty Ltd 
ACN 74 082 016 626
Contact:
Mr Peter Robert, Executive Director 
Phone:
+61 3 9686 5022
Fax:
+61 3 9686 5033
Email:
Internet:
 Address:
182 -184 Ferrars StreetSouth Melbourne, VIC, 3205Australia
Profile:
 Advanced Laboratory Solutions Pty. Ltd., trading as Advanced Labs, offers ‘next generation’  platform technology to the Australian scientific and medical research community. Their goal is tooffer this technology in a timely manner so as to maximize the Australian scientific community'sability to remain globally competitive. Advanced Labs’ core industry focus is genomics, proteomics, bioinformatics, drug discovery, pharmaceutical manufacturing, and biotechnology. The company invests significant resources inthe Australian and USA markets, in order to rapidly transfer knowledge from centers of researchexcellence (such as Stanford and Harvard Universities and the National Institutes of Health - NIH)to Australian customers. The company is successfully transferring the skills developed in thismarket to other customers within the Pacific Rim. Advanced Labs’ goal is to be a successful, respected, ‘Technology Partner’ to its target market.Core components of this vision are a global support network, an educated and dynamic Sales &Marketing Department, a responsive customer service team, and factory-trained serviceengineers. As an example, Advanced Labs in conjunction with the Peter MacCallum Cancer Institute entered into a joint 'Technology Evaluation Program' in 1999. The outcome of this relationship was therapid integration and knowledge transfer of microarray manufacturing to Australian scientists, theselection of the most appropriate platform technology for the Australian market, and thesubsequent decision by four additional core research precincts to adopt identical technology, thusaiding and accelerating Australia's push into the international business of medical genomics.
 
Advent Pharmaceuticals Pty Ltd 
ACN 43 095 494 563
Contact:
Dr Jill Snell, General Manager 
Phone:
+61 3 8562 2235
Fax:
+61 3 8562 2288
Email:
 Address:
Monash Enterprise Centre5a Harnett CloseMulgrave, VIC, 3170Australia
Profile:
 Advent Pharmaceuticals is a technology development company specialising in the development of novel dry powder inhalation delivery platforms. The focus of Advent’s product development isdirected initially at novel platforms for the management of asthma and chronic obstructive pulmonary disease, with future therapeutic applications in new pulmonary delivered medications.Established in January 2001, Advent Pharmaceuticals is an Australian-registered, privately owned company. Advent’s product design, development and preclinical testings are presently conducted in Victoria, Australia. Clinical, regulatory and manufacturing will be outsourced to local and international contract organisations.
AgGenomics Pty. Ltd. 
ACN 16 099 612 423
Contact:
Dr Glenn Tong, Managing Director 
Phone:
+61 3 8412 7066
Fax:
+61 3 9417 4076
Email:
Internet:
 Address:
60-66 Hanover StreetFitzroy, VIC, 3065Australia
Postal  Address:
P. O. Box 115Fitzroy, VIC, 3065Australia
Profile:
 AgGenomics Pty. Ltd. was formed in March 2002 as a joint venture between Genetic TechnologiesLimited (ASX-GTG) and Agriculture Victoria Services Pty Ltd (the commercial arm of the VictorianGovernment's Department of Natural Resources and Environment). This joint venture, the first ultra high throughput genomics facility in Australasia, will dramatically improve the efficiency of traditional plant and animal breeding programs via the use of ultra high throughput genomicstechnologies. AgGenomics has unique enabling technologies, expertise and extensive experience in theidentification of genetic markers linked to commercially important traits in a wide variety of plant species. The same technology is also applicable to animal species. The development of genetic markers such as SNPs, microsatellites (SSRs) and AFLPs and the application of these markers inmarker assisted selection (MAS) is AgGenomics’ key strength and primary business activity. AgGenomics has extremely high throughput capabilities, with a capacity of well over 20,000 genotype analyses per day using a suite of state-of-the-art automated technology platforms.These capabilities allow plant and animal breeders to deliver improved varieties to the market quicker and more economically through the use of MAS. AgGenomics also has expertise and experience in cultivar identification, eg for Plant Breeders’ Rights and transgene detection. AgGenomics primarily operates on a fee-for-service basis, with no participation in the sharing of intellectual property. In certain circumstances, such as genetic marker discovery programs which are linked to a marker assisted selection program requiring ultrahigh throughput genotyping, AgGenomics may also enter into collaborative R&D programs on acost and IP sharing basis.

Activity (13)

You've already reviewed this. Edit your review.
1 hundred reads
1 thousand reads
Peter Johnson liked this
Sony Chandran liked this
paul_costas liked this
ZernikeAU liked this
usman283 liked this
shahjitu liked this
shawtylikemine liked this

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->